Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-03-20
2002-04-23
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S312000, C544S314000
Reexamination Certificate
active
06376504
ABSTRACT:
FIELD OF THE INVENTON
The present invention is directed to novel PBT and DABO derivatives. In one particular embodiment, the invention is directed to novel PBT and DABO derivatives that exhibit spermicidal activity.
BACKGROUND OF THE INVENTION
Human immunodeficiency virus (HIV), the etiologic agent of acquired immunodeficiency syndrome (AIDS), is the fastest growing cause of death in women of reproductive age. Heterosexual transmission accounts for 90% of all HIV infections worldwide and constitutes a growing proportion of new HIV infections in the United States. By the year 2000, thirteen million women will be infected with HIV out of a worldwide total of 40 million HIV-infected individuals. In the absence of an effective prophylactic anti-HIV vaccine or antiretroviral therapy, female-controlled vaginal microbicides for curbing mucosal and perinatal HIV transmission are needed.
There is concern that worldwide use of detergent spermicides, such as nonoxynol-9 (N-9) might actually increase the risk of HIV transmission. N-9 has been used for more than 30 years in over-the-counter gels, foams, creams, sponges, films, and foaming tablets designed to kill sperm. Because N-9 has been shown to inactivate HIV in vitro, it is the only topical microbicide currently under consideration for protection against sexually transmitted HIV infection in women. However, the main drawback of using N-9 is its detergent-type effect on epithelial cells. Frequent use of N-9 as a vaginal contraceptive has been associated with an increased risk of cervicovaginal infection, irritation, or ulceration. Since continued use of N-9 can alter the vaginal flora and promote opportunistic infections, it can enhance the susceptibility of the ectocervical epithelium and endocervical mucosa to HIV infection. Furthermore, recent clinical trials have shown that vaginal contraceptives containing N-9 had no effect on the transmission of HIV/AIDS and other STDs when provided as part of an overall prevention program to prevent heterosexual transmission of HIV/AIDS. See, for Example, Roddy et. al., 1998
, N.Eng.J Med
. 339:504-510; Hira et.al., 1997
, Int. J. STD AIDS
8:243-250)
New, effective, safe, and female-controlled topical microbicides lacking detergent-type membrane toxicity should have clinical advantage over the currently available vaginal microbicides. Physiological fertilization depends on the ability of the ejaculated sperm to swim, bind the zona pellucida, and penetrate the egg. Each of these activities is primarily dependent on sperm motility. Therefore, adding spermicidal function to antiretroviral drugs of choice, such as non-nucleoside inhibitors (NNIs), could be an effective way to curb heterosexual vaginal transmission of HIV as well as prevent conception.
SUMMARY OF THE INVENTION
The present invention provides novel nonnucleoside inhibitors (NNIS) which are phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives. These compounds are useful as sperm immobilizing or contraceptive agents. To applicants' knowledge, PBT and DABO derivatives have not previously been studied and recognized as having any contraceptive, e.g., spermicidal, or sperm-inmobilizing, activity.
The invention provides halogenated PBT derivatives having the chemical structure (I), or a pharmaceutically acceptable salt thereof:
where R, R
1
6
, R
2
, R
3
, and R
4
are independently hydrogen, F, Cl, Br, or I, and where at least one of R, R
1
, R
2
, R
3
, and R
4
is F, Cl, Br, or I.
The invention also provides a novel DABO derivative compound comprising the formula (III):
where R
1
and R
2
are alike or different, and are hydrogen, halo, alkyl, alkenyl, hydroxy, alkoxy, thioalkyl, thiol, phosphino, ROH, or RNH group, where R is alkyl; Y is S or O; and R
3
is alkyl, alkenyl, aryl, aralkyl, ROH, or RNH
2
group, where R is alkyl; or a pharmaceutically acceptable salt thereof.
The invention additionally provides a method of inhibiting conception in a mammal. The method comprises contacting mammalian sperm with an effective spermicidal amount of a novel halogenated PBT derivative or a novel DABO derivative of the invention.
Another aspect of the invention is a method for inhibiting the motility of sperm. The method comprises contacting sperm with a sperm mobility-inhibiting effective amount of a halogenated PBT derivative or a DABO derivative of the invention.
The invention also provides a composition comprising an effective spermicidal amount of a spermicidal agent, and a pharmaceutically acceptable carrier, diluent, or vehicle. The spermicidal agent comprises a halogenated PBT derivative or a DABO derivative of the invention.
The invention also provides a spermicidal article comprising a halogenated PBT derivative or a DABO derivative of the invention.
Other aspects of the invention will become apparent to those skilled in the art upon review of the following drawings, detailed description, examples and claims.
REFERENCES:
patent: 5112835 (1992-05-01), Miyasaka et al.
patent: 5593993 (1997-01-01), Morin, Jr. et al.
patent: 5658907 (1997-08-01), Morin, Jr. et al.
patent: 5686428 (1997-11-01), Eriksson et al.
patent: 5714503 (1998-02-01), Morin, Jr. et al.
patent: 5786462 (1998-07-01), Schneider et al.
patent: 5998411 (1999-12-01), Vig et al.
patent: 6136335 (2000-10-01), Uckun et al.
patent: 0 420 763 (1991-04-01), None
patent: 0 540 143 (1992-05-01), None
patent: 07025770 (1995-01-01), None
patent: WO 93/03022 (1993-02-01), None
patent: WO 95/06034 (1995-03-01), None
patent: WO 99/47501 (1999-09-01), None
patent: WO 00/03998 (2000-01-01), None
Ahgren, C., et al., 1995,Antimicrob. Agents Chemotherapy, 39, 1329-1335 The PETT Series, a New Class of Potent Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase.
Baba, M., et al., 1992,Antiviral Res., 17, 245-264 Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives.
Balzarini, J. et al., 1992,Proc. Natl. Acad. Sci. U S A, 89, 4392-4396 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide)pyrimidine(TSAO) nucleoside analogues: Hightly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
Bartlett, P.A. et al., 1989,Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules.
Bell, F. W., et al., 1995,J. Med. Chem., 38, 4929-4936 Penethylthaizolethiourea (PETT) Compounds, a New Class of HIV-1 Reverse Transcriptase Inhibitors. 1. Syntheis and Basic Structure-Activity Relationship Studies of PETT Analogs.
Blaney, J.M. and Dixon, J.S., 1993,Perspectives in Drug Discovery and Design, 1, 301 A good ligand is hard to find: Automated docking methods.
Bohm, H. J., 1992,J. Comput. Aided. Mol. Des., 6, 593-606 LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads.
Bohm, H.J., 1992,J. Comp. Aid. Molec. Design, 6, 61-78 The computer program LUDI: A new mehtod for the de novo design of enzyme inhibitors.
Bohm, H. J.,J. Comput. Aided. Mol. Des., 1994, 8, 243-256; 1996 The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of knwon three-dimensional structure.
Bosworth, N., et al., 1989,Nature, 341: 167-168 Scintillation proximity assay.
Brooks, B.R. et al., 1983,J. Comp. Chem., 4, 187-217 CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations.
Burkert, U. and Allinger, N.L., 1982, Molecular Mechanics,ACS Monograph, 177, 59-78, American Chemical Society, D.C. Methods for the Computation of Molecular Geometry.
Cantrell, A. S., et al., 1996,J. Med. Chem., 39, 4261-4274 Phenethylthiazolythiourea (PETT) Compounds as a New Class of HIV-1 Reverse Transcriptase Inhibitors. 2. Synthesis and Further Structure-Activity Relationship Studies of PETT Analogs.
Chemical substance index page,Chemical Abst
D'Cruz Osmond
Uckun Fatih M.
Balasubramanian Venkataraman
Merchant & Gould
Parker Hughes Institute
Raymond Richard L.
LandOfFree
Phenethyl-5-bromopyridlythiourea (PBT) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenethyl-5-bromopyridlythiourea (PBT) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenethyl-5-bromopyridlythiourea (PBT) and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2889401